Equasens (CHIX:EQSP) Beta: -0.2654 (As of Jun. 25, 2026)


CHIX:EQSP Equasens CHIX:EQSP
85 GF Score
Price €38.48
GF Value €50.68
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Equasens Beta?

Equasens CHIX:EQSP 85 Beta is -0.2654 as of Jun. 25, 2026. GuruFocus rates CHIX:EQSP with a GF Score™ of 85/100 and a GF Value™ of €50.68 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Equasens's Beta is -0.2654.


Equasens  (CHIX:EQSp) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Equasens Beta Related Terms


Equasens Beta Historical Data

* Premium members only.

The historical data trend for Equasens's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Equasens Beta Chart

Equasens Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.41 -0.17 -0.33

Equasens Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.19 -0.17 0.01 -0.33

CHIX:EQSP vs VEEV, BTSG, TEM: Beta Comparison

For the Health Information Services subindustry, Equasens's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equasens Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Equasens's Beta distribution charts can be found below:

* The bar in red indicates where Equasens's Beta falls into.


CHIX:EQSP
85GF Score
Equasens CHIX:EQSP
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equasens Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2654 mean?
Equasens (CHIX:EQSP) has a Beta of -0.2654 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Equasens and its competitors.
Is Equasens' Beta too high?
Equasens' current Beta is -0.2654. Overall, Equasens has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Equasens' Beta compare to VEEV and BTSG?
Equasens' Beta of -0.2654 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Equasens and its competitors. Equasens's current Beta is -0.2654. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Based on GuruFocus' analysis, Equasens (CHIX:EQSP) is currently considered Modestly Undervalued. The stock's GF Value™ is €50.68, compared to a current price of €38.48 — trading 24.1% below its estimated fair value. The current Beta is -0.2654. Equasens' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Equasens (CHIX:EQSP), the current Beta is -0.2654 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equasens (CHIX:EQSP) Overvalued in 2026?

Based on GuruFocus' analysis, Equasens stock appears to be undervalued. The current stock price of €38.48 is trading 24.1% below its estimated GF Value™ of €50.68. GuruFocus considers Equasens to be Modestly Undervalued.

Key valuation signals for CHIX:EQSP:

  • Beta: -0.2654
  • GF Value™: €50.68 vs. price of €38.48 (24.1% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the CHIX:EQSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Equasens Business Description

Address 5 Allee de Saint-Cloud, Technopole de Nancy Brabois, Villers-les-Nancy, FRA, 54600
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
85GF Score

Get the complete analysis for CHIX:EQSP

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.48
Price
€50.68
GF Value